Introduction
The microenvironment is a key player in tumor development (1) . Tumor microenvironment comprises stromal cells and endothelial cells. When tumor development is associated to a host inflammatory reaction, infiltrating leukocytes from the blood become also part of the microenvironment. Myeloid cells often infiltrate tumors, and their pro or anti-tumoral role, especially with macrophages, has been extensively studied (2, 3) .
In addition to the well-described role for macrophages, a role for neutrophils in the development of tumors has been recently proposed (4) . Neutrophils have been reported to increase cancer genetic instability by their production of nitric oxide derivatives and reactive oxygen species (5) , to promote angiogenesis by their secretion of pro-angiogenic factors (6, 7) , and also to produce immunosuppressive factors, such as IL-10 (8). For all these reasons, neutrophil infiltration of several solid tumors has been associated with a poorer outcome for patients (9) . On the other hand, neutrophils may also act as anti-tumoral immune cells via their expression of the apoptotic ligand TRAIL (10). Furthermore, elastase, a protease commonly secreted by neutrophils, is also an anti-angiogenic factor (11) . Hence, the role of neutrophils in tumor development is contrasted, and it is believed that neutrophils may be polarized, in effector cells with either pro-or anti-tumoral function, very similarly to macrophages (12) .
Neutrophils produce a proliferation inducing ligand (APRIL, TNFSF13) (13) . The initial reported function of APRIL was induction of increased proliferation in tumor cells (14) . This role has been further substantiated in colorectal cancers (15) . Hematologic tumors from the B-cell lineage also depend on APRIL (16) . The best-documented B-cell malignancy depending on APRIL is chronic lymphocytic leukemia (CLL). In CLL, APRIL is of stromal origin, and prolongs the in vitro survival of primary CLL samples (17, 18) . Furthermore, APRIL overexpression in mice leads to CLL-like neoplasm development. In patients, high APRIL serum level correlates with reduced patient survival (19) (20) (21) (22) . Regarding DLBCL, APRIL also acts as an in vitro survival factor (23), and a high level of APRIL in tumor lesions is a risk factor, at least in patients treated with CHOP chemotherapy (24). While DLBCL tumor cells may aberrantly produced APRIL upon translocations involving the APRIL gene and the immunoglobulin heavy chain locus (25), we previously observed that most of APRIL originates from infiltrating neutrophils (24). Here, we are describing the pathway conducting to high APRIL expression in DLBCL lesions.
Methods

Human and animal experimentations
The Basel and Grenoble ethical committees approved human experimentations. The basel DLBCL cohort has been previously described (26). Frozen DLBCL biopsies and corresponding formalin-fixed paraffin-embedded DLBCL biopsies used for mRNA analysis were obtained after patients' informed consent from the centre of biological resources (Grenoble, France). Two pathologists independently reviewed DLBCL diagnosis. In some cases, GC and non-GC DLBCL subtypes were defined by immunohistochemistry with the combination of CD10, bcl-6 and Mum-1/IRF-4 markers as reported (27) . Peripheral blood leukocytes were obtained from healthy donors 
Neutrophil stimulation
Neutrophils were purified following standard dextran sedimentation followed by Ficollpaque centrifugation and FACS-sorting based on FSC high SSC high morphology on a FACS-Aria (BD Biosciences). After purification CD13 + CD16 + neutrophils represented more than 85% and 80%, respectively. Viability assessed by trypan blue staining was > 95% after 24 h. Conditioned supernatants were obtained by incubating neutrophils at 10 6 cells per ml in RPMI 1640
supplemented with 10% heat-inactivated FCS. Cell stimulation was performed with either fMLP (6.10 -9 M, Sigma) or phorbol 12-myristate 13-acetate (PMA, 50 ng/ml, Sigma) or TNF (100 ng/ml, Adipogen). Cell-free supernatant was analysed for secreted APRIL by ELISA using manufacturer's instructions (eBioscience). Cells were also harvested for APRIL mRNA expression at 6 and 12 h.
For the analysis of H 2 O 2 production, 0.5 x 10 6 cells were mixed in a 96-well plate with 20 mM glucose, 20 µM luminol and 10U/ml HRP and with the activators described above.
Luminescence was recorded at 37°C every 15 s for 10 min using a Victor3 1420 multilabel counter (Perkin Elmer).
Immunohistochemistry
Biopsies were stained for APRIL-producing cells (Stalk-1 staining), elastase, and CD20
as previously described (24). Rabbit anti-CXCL-8 (Life technologies) was used at 5 µg/ml after heat-induced antigen retrieval in 10 mM Tris, 1 mM EDTA pH 9.0. Microscopy images were visualized with a BX-41 microscope (Olympus) with a plan 40x/0,65 air objective and a plan 100x/1,25 oil objective. Images were captured with a DP70 color camera and treated with the AnalySIS software. Confocal analysis was performed on an LSM 510 microscope (Carl Zeiss) with a plan 40x/1.30 oil-immersion objective.
Flow cytometry
All fluorochrome-conjugated antibodies were from BD biosciences. APRIL staining with Stalk-1 (detecting APRIL-producing cells) was performed after cell permeabilization as previously described (24). Fluorescence was analysed by flow cytometry on a FACS CALIBUR or an Accuri C6 (BD biosciences). CD20 + and CD20 -fraction of frozen primary DLBCL were purified by FACS-sorting on a FACS-Aria (BD biosciences). CD19 + B-cell subsets were purified from tonsils according to naive (IgD + /CD38 -), GC (CD38 + ) and memory (IgD  -/CD38  -) phenotype. Dead cells were excluded by 7-AAD staining. Purity and viability was > 95%.
PCR
For the detection of ELC-CXC chemokine mRNA, 30 sections of 20 µm from frozen DLBCL biopsies were pooled, and total RNA was extracted with the RNeasy micro kit (Qiagen).
cDNA was generated using random primers and the SuperScript II reverse transcriptase (Invitrogen). For CXCL-2 5'-ctttccagccccaaccat-3' and 5'-ggatttgccatttttcagca-3', for CXCL-3 , for CCL-7 5'-cagaaggaccaccagtagcc-3' and 5'-gcatcccacagtttttacagc-3', for CCL-13 5'-cagaggagcagagaggcaaa-3'  and  5'-gccagaggagaatggaaaagtc-3',  for  CCL-14  5'-gctctcctcccacaacagc-3' and 5'-gccaatgagtaaatcccgtaga-3' were used as forward and reverse primers, respectively. Denaturation was performed at 94°C, annealing at 55°C and extension at 72°C, 1 mn each. Forty cycles were applied. Amplified PCR products were visualized on agarose gels and ethidium bromide staining. To exclude genomic DNA amplification, primers spanning intronic sequences were used.
For quantitative analysis, total RNA was extracted using Trizol (Invitrogen), and cDNA generated as above. Quantification was performed using the iCycler iQ Real-Time PCR Detection system (Bio-Rad) and a SYBRgreen-based kit (iQ SupermixBio-Rad). The intron spanning forward 5'-atgggtcaggtggtgtctcg-3' and reverse 5'-tccccttggtgtaaatggaaga-3' primers were used for the detection of human APRIL. Expression levels were normalized using 18S
rRNA. Results were quantified using a standard curve generated with serial dilutions of input DNA. 
Chemokine profiling and ELISA
Epigenetic studies
0.5 x 10 6 DLBCL cells per ml were incubated for 24 h with Trichostatin A (TSA, 500 ng/ml, Sigma) or 72 h with Decitabine (10 µM, Sigma). DMSO was used as a vehicle control.
Real time RT-PCR was performed as described above with forward and reverse primers for CXCL-8 5'-cggaaggaaccatctcactg-3' and 5'-agcactccttggcaaaactg-3', respectively. Expression levels were normalized using actin mRNA. Results were quantified using a standard curve generated with serial dilutions of input DNA.
Statistics
Data are presented as means ± s.d. Statistical analyses were performed with two-tailed unpaired Mann-Whitney U test on samples of equal size using the Prism software (Graphpad Software Inc., San Diego, CA, USA). P-values superior to 0.05 were considered as nonsignificant.
Results
Blood neutrophils constitutively produce APRIL
Neutrophils usually produce their effector proteins at an immature stage and store these proteins in intracellular granules to release them upon activation at the inflammation site (30).
Transcription of neutrophil effector proteins is commonly stopped at neutrophil maturity. We previously reported that APRIL production is also switched on early in immature neutrophils, but APRIL transcription drops by two third but does not stop in mature neutrophils, at least for mature neutrophils present in bone marrow (BM) (31). In the blood circulation, APRIL transcription in neutrophils did not stop as well, and was equal to that in mature neutrophils from 
DLBCL tumor cells variably express the chemokine CXCL-8
The mechanism by which APRIL production varies in DLBCL lesions is presently unknown. Our previous work indicated that infiltrating neutrophils are a cellular source of 
CXCL-8 recruits APRIL-producing neutrophils in DLBCL lesions
In vitro CXCL-8 + DLBCL cell lines attracted significantly more neutrophils in a standard 
CXCL-8 production in DLBCL is a post-transformation event
Among the 11 CXCL-8 + DLBCL cell lines, bcl-2 expression was detected in 7 of them.
All the cell lines expressed the B-cell marker CD19, except one. All of them expressed HLA-DR. Taken together, these experiments showed that the CXCL-8 -DLBCL cell lines tested here still contain a functional CXCL-8 locus, and this locus is kept silent by DNA methylation and histone hypoacetylation.
Discussion
In the present study, we observed a constitutive production of APRIL by blood circulating neutrophils. These cells do not store APRIL in exocytosis granules but rather constantly secrete 
